AI
AXSM icon

Axiom Investors’s Axsome Therapeutics AXSM Stock Holding History

Axiom Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.55M Sell
56,529
-6,861
-11% -$1.19M 0.11% 79
2025
Q4 		$11.6M Buy
63,390
+14,137
+29% +$1.97M 0.1% 78
2025
Q3 		$5.98M Buy
49,253
+22,147
+82% +$2.49M 0.04% 94
2025
Q2 		$2.83M Buy
27,106
+799
+3% +$84.6K 0.02% 117
2025
Q1 		$3.07M Buy
+26,307
New +$3M 0.03% 113

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axiom Investors's AXSM Position: Q1 2026 in Review

Axiom Investors reduced its Axsome Therapeutics (AXSM) stake by 11% in Q1 2026, selling an estimated $1.19M and leaving 56,529 shares worth $9.55M. The position accounts for 0.11% of the portfolio, ranked #79.

Axiom Investors first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.6M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Axiom Investors held 56,529 shares of Axsome Therapeutics worth $9.55M as of Q1 2026.
  • Axiom Investors sold 6,861 Axsome Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Axsome Therapeutics made up 0.11% of Axiom Investors's portfolio in Q1 2026, its #79 holding.
  • Axiom Investors first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Axiom Investors's Axsome Therapeutics position peaked at $11.6M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Axiom Investors's 13F filing for Q1 2026, filed 14 May 2026.